Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram

BACKGROUND: Sorafenib, a kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC) but provides only a limited survival benefit. Disulfiram (DSF), a drug for treating alcoholism and a chelator of copper (Cu), forms a complex with Cu (DSF/Cu). DSF/Cu is a potent inducer of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Gong, Wang, Yufeng, Fuchs, Bryan C., Guo, Wei, Drum, David L., Erstad, Derek J., Shi, Baomin, DeLeo, Albert B., Zheng, Hui, Cai, Lei, Zhang, Liyuan, Tanabe, Kenneth K., Wang, Xinhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329590/
https://www.ncbi.nlm.nih.gov/pubmed/35912209
http://dx.doi.org/10.3389/fonc.2022.913736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329590/
https://www.ncbi.nlm.nih.gov/pubmed/35912209
http://dx.doi.org/10.3389/fonc.2022.913736

Ejemplares similares